Article
Rheumatology
Nicolino Ruperto, Hermine Brunner, Cesar Pacheco-Tena, Ingrid Louw, Gabriel Vega-Cornejo, Alberto J. Spindler, Daniel J. Kingsbury, Heinrike Schmeling, Arturo Borzutzky, Ruben Cuttica, C. J. Inman, Victor Malievskiy, Christiaan Scott, Vladimir Keltsev, Maria Teresa Terreri, Diego Oscar Viola, Ricardo M. Xavier, Taciana A. Pedrosa Fernandes, Maria Del Rocio Maldonado Velazquez, Michael Henrickson, Michael B. Clark, Karen A. Bensley, Xiaoming Li, Kim Hung Lo, Jocelyn H. Leu, Chyi-Hung Hsu, Elizabeth C. Hsia, Zhenhua Xu, Alberto Martini, Daniel J. Lovell
Summary: Intravenous golimumab was effective, showed consistent pharmacokinetics, and was relatively safe in pediatric patients with polyarticular-course JIA. Treatment led to significant JIA ACR response rates at 28 and 52 weeks, with steady PK exposure maintained. However, the presence of antibodies in some patients and rare serious infections were noted as potential issues.
Article
Rheumatology
Nicolino Ruperto, Hermine Brunner, Athimalaipet Ramanan, Gerd Horneff, Ruben Cuttica, Michael Henrickson, Jordi Anton, Alina Lucica Boteanu, Inmaculada Calvo Penades, Kirsten Minden, Heinrike Schmeling, Markus Hufnagel, Jennifer E. Weiss, Manuela Pardeo, Kabita Nanda, Johannes Roth, Nadina Rubio-Perez, Joy C. Hsu, Sunethra Wimalasundera, Chris Wells, Kamal Bharucha, Wendy Douglass, Min Bao, Navita L. Mallalieu, Alberto Martini, Daniel Lovell, Fabrizio De Benedetti
Summary: The study found that the dosing regimens of s.c. tocilizumab in systemic JIA and polyarticular JIA are similar to i.v. tocilizumab with good efficacy. Additionally, the subcutaneous administration route is more convenient and suitable for at-home use.
Article
Rheumatology
B. Schiappapietra, C. Bava, S. Rosina, A. Pistorio, F. Mongelli, S. Pederzoli, S. Verazza, S. Lanni, V Muratore, S. Davi, S. Dalpra, G. C. Varnier, M. Bertamino, C. Suffia, G. Bracciolini, G. Giancane, A. Consolaro, A. Ravelli
Summary: The number of affected joints and the CRP level in the first 6 months were identified as the strongest predictors of polyarticular extension in children with oligoarticular-onset JIA.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2021)
Article
Rheumatology
Laura E. Schanberg, Lily (Yeruk) Mulugeta, Bolanle Akinlade, Hermine I. Brunner, Jianmeng Chen, Robert A. Colbert, Vincent Delgaizo, Marc R. Gastonguay, Rachel Glaser, Lisa Imundo, Daniel J. Lovell, Jocelyn H. Leu, Nael M. Mostafa, Robert M. Nelson, Peter A. Nigrovic, Nikolay P. Nikolov, Lisa G. Rider, Rebecca Rothwell, Chandrahas Sahajwalla, Renu Singh, Vikram Sinha, Carolyn L. Yancey, Lynne Yao
Summary: This report summarizes a workshop on drug development for polyarticular juvenile idiopathic arthritis (pJIA), highlighting the importance of accelerating drug development and the necessity of collaboration between stakeholders.
ARTHRITIS & RHEUMATOLOGY
(2023)
Review
Biology
Sydney Moore McIntosh, Christian Kerut, Payton P. Hollenshead, Dorothy H. Askins, Kasra Mansourian, Zachary R. Palowsky, Varsha Allampalli, Shahab Ahmadzadeh, Sahar Shekoohi, Alan D. Kaye
Summary: Psoriatic arthritis is a chronic autoimmune condition with unique cutaneous manifestations. Tumor necrosis factor inhibitors, such as golimumab, have become a hallmark treatment option. Multiple studies have shown the efficacy of golimumab in both juvenile and adult-onset psoriatic arthritis.
Article
Immunology
Jie Zheng, Yong Wang, Jun Hu
Summary: This study explores the shared gene signatures and potential molecular mechanisms of polyarticular juvenile idiopathic arthritis (pJIA) and autoimmune uveitis (AU) through data analysis and functional enrichment analysis. Neutrophil degranulation may be considered a shared pathogenic mechanism, and the roles of ARID1A gene and hsa-miR-146a are worthy of further study. Additionally, periodic inspection of kidney function is also important.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Rheumatology
Hema Chaplin, Lewis Carpenter, Anni Raz, Elena Nikiphorou, Heidi Lempp, Sam Norton
Summary: The study identified that refractory disease in RA and polyJIA is defined mainly as resistance to multiple drugs with different mechanisms of action and persistence of symptoms and high disease activity. It is concluded that there is a need for a clear unified definition to aid study comparisons and appropriate identification of patients.
Article
Rheumatology
Jelena Vojinovic, Ivan Foeldvari, Joke Dehoorne, Violeta Panaviene, Gordana Susic, Gerd Horneff, Valda Stanevicha, Katarzyna Kobusinska, Zbigniew Zuber, Bogna Dobrzyniecka, Jonathan Akikusa, Tadej Avcin, Cecilia Borlenghi, Edmund Arthur, Svitlana Y. Tatulych, Chuanbo Zang, Vassilis Tsekouras, Bonnie Vlahos, Alberto Martini, Nicolino Ruperto
Summary: CLIPPER2 is an 8-year study on the safety and efficacy of etanercept in patients with juvenile idiopathic arthritis (JIA). The study found that etanercept treatment was well tolerated and effective in these patients.
Article
Ophthalmology
Achille Marino, Luca Marelli, Paolo Nucci, Roberto Caporali, Elisabetta Miserocchi
Summary: This study aimed to evaluate the efficacy and safety of subcutaneous tocilizumab in JIA patients with refractory uveitis. The results showed that SC-TCZ significantly reduced the rate of uveitis flare and achieved complete treatment response in some patients. Moreover, SC-TCZ was well-tolerated without any observed side effects.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2023)
Article
Medicine, General & Internal
Monika Ostrowska, Emil Michalski, Piotr Gietka, Malgorzata Manczak, Magdalena Posadzy, Iwona Sudol-Szopinska
Summary: This study compared MRI findings between patients clinically suspected of Juvenile Idiopathic Arthritis (JIA) and patients with ankle arthralgia of unknown cause. The results showed that inflammatory features were observed on MRI, with tenosynovitis being significantly more common in JIA patients. However, the MRI summarized score did not effectively differentiate between JIA and non-JIA patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Pediatrics
Xuefeng Xu, Xiaohui Liu, Wenjie Zheng, Jihong Xiao, Xiaozhong Li, Ling Wu, Lixia Zou, Qian Ouyang, Yaoyao Shangguan, Kezhao Lin, Xiaomei Dai, Yuanling Chen, Yiping Xu, Jianqiang Wu, Meiping Lu
Summary: This study suggests that the combination of rhTNFR-Fc and MTX significantly improves symptoms and disease activity in children with JIA.
FRONTIERS IN PEDIATRICS
(2022)
Review
Biochemistry & Molecular Biology
Magdalena Wojdas, Klaudia Dabkowska, Katarzyna Winsz-Szczotka
Summary: Juvenile idiopathic arthritis (JIA) is the most common chronic connective tissue disease in children, characterized by inflammation-induced destruction of articular cartilage. Understanding the metabolic changes in extracellular matrix (ECM) components in the course of JIA may lead to the introduction of new therapeutic strategies for children with JIA, beyond just diagnosing disease activity.
Article
Rheumatology
Julie A. Campbell, Susan Shenoi
Summary: This case series investigates the characteristics of 12 patients diagnosed with juvenile idiopathic arthritis (JIA) at younger than 12 months. The results show that children with infantile JIA are overall similar to older children with JIA, but there is a larger delay in diagnosis and a high prevalence of joint contractures.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
(2022)
Article
Allergy
Koichi Sugihara, Risa Wakiya, Hiromi Shimada, Mikiya Kato, Tomohiro Kameda, Shusaku Nakashima, Mai Mahmoud Fahmy Mansour, Yusuke Ushio, Norimitsu Kadowaki, Hiroaki Dobashi
Summary: Tocilizumab treatment may lead to the development of interstitial lung disease in patients with JIA, but symptoms can be alleviated with glucocorticoid therapy.
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Tingyan He, Jiayun Ling, Jun Yang
Summary: This study describes the incidence of TCZ-induced hypofibrinogenemia in SJIA patients and its possible influence on bleeding risk.
SCIENTIFIC REPORTS
(2023)
Article
Rheumatology
Sindhu R. Johnson, Dafna D. Gladman, Hermine Brunner, David Isenberg, Ann E. Clarke, Megan R. W. Barber, Laurent Arnaud, Paul R. Fortin, Marta Mosca, Alexandre E. Voskuyl, Susan Manzi, Cynthia Aranow, Anca Askanase, Graciela S. Alarcon, Sang-Cheol Bae, Nathalie Costedoat-Chalumeau, Jessica A. English, Guillermo J. Pons-Estel, Bernardo A. Pons-Estel, Rebecca Gilman, Ellen M. Ginzler, John G. Hanly, Soren Jacobsen, Kenneth Kalunian, Diane L. Kamen, Chynace Lambalgen, Alexandra Legge, S. Sam Lim, Anselm Mak, Eric F. Morand, Christine A. Peschken, Michelle Petri, Anisur Rahman, Rosalind Ramsey-Goldman, John A. Reynolds, Juanita Romero-Diaz, Guillermo Ruiz-Irastorza, Jorge Sanchez-Guerrero, Elisabet Svenungsson, Zahi Touma, Murray Urowitz, Evelyne Vinet, Ronald F. van Vollenhoven, Heather Waldhauser, Daniel J. Wallace, Asad Zoma, Ian N. Bruce
Summary: The SLICC, ACR, and Lupus Foundation of America are developing a revised SLE damage index (SDI) due to shifts in the concept of damage in SLE. A qualitative study was conducted to evaluate contemporary constructs in SLE damage and develop a conceptual framework for the revised SDI.
ARTHRITIS CARE & RESEARCH
(2023)
Review
Rheumatology
Rafaela Cavalheiro do Espirito Santo, Joshua F. Baker, Leonardo Peterson dos Santos, Mariana Marchezan Menezes da Silva, Ricardo Machado Xavier
Summary: This review summarizes the evidence on the prevalence and impact of sarcopenia in patients with rheumatic diseases. It concludes that sarcopenia is common among these patients, and its impact is often underestimated. The implementation of treatment strategies for sarcopenia in this population is still limited.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
(2023)
Article
Rheumatology
Joana S. Carvalho, Edgard T. dos Reis Neto, Adriana M. Kakehasi, Sandra L. E. Ribeiro, Samia A. S. Studart, Francielle P. Martins, Rafaela Cavalheiro do Espirito Santo, Aline Ranzolin, Diana C. Fernandino, Valquiria G. Dinis, Emilia Sato, Gustavo G. Resende, Adriana Marinho, Henrique A. Mariz, Nathalia C. Sacilotto, Francinne M. Ribeiro, Samuel K. Shinjo, Laiza H. Dias, Michel A. Yazbek, Felipe Omura, Thiago Hs Rached, Ana Paula M. Gomides, Claudia D. L. Marques, Gecilmara C. S. Pillegi, Licia M. H. Mota, Marcelo M. Pinheiro, Odirlei A. Monticielo, Ricardo M. Xavier, Gilda A. Ferreira
Summary: This study aimed to evaluate factors associated with COVID-19 severity outcomes in patients with systemic lupus erythematosus (SLE). SLE patients with COVID-19 showed a lower frequency of social isolation and a higher chance of hospitalization with hypertension and cyclophosphamide. Telemedicine support was found to be beneficial for SLE patients with COVID-19.
Article
Pediatrics
Ellen M. Cody, Scott E. Wenderfer, Kathleen E. Sullivan, Alfred H. J. Kim, Wesley Figg, Harneet Ghumman, Tingting Qiu, Bin Huang, Prasad Devarajan, Hermine Brunner
Summary: The Renal Activity Index for Lupus (RAIL) can non-invasively identify lupus nephritis (LN) and assess the efficacy of LN induction therapy. RAIL scores can differentiate clinically active LN from inactive LN or without LN. RAIL scores significantly decrease after complete LN remission.
PEDIATRIC NEPHROLOGY
(2023)
Article
Rheumatology
Camilla Ribeiro Lima Machado, Adriana Maria Kakehasi, Felipe Ferraz Dias, Gustavo Gomes Resende, Patricia Gnieslaw de Oliveira, Ricardo Machado Xavier, Marcus Vinicius Melo de Andrade
Summary: This study analyzed the ultrastructural characteristics, IL-6 and MMP-3 production, and intracellular pathway activation in FLS cultures from rheumatoid arthritis patients and mice with collagen-induced arthritis. The results showed similarities in ultrastructural morphology and cytokine production between the two sources, but a lower response to IL-1 beta was observed in CIA-FLS compared to RA-FLS.
ADVANCES IN RHEUMATOLOGY
(2023)
Review
Rheumatology
Emerson Pena, Leonardo Peterson dos Santos, Rafaela Cavalheiro do Espirito Santo, Silvia Guaresi, Vania Naomi Hirakata, Thais Evelyn Karnopp, Ricardo Machado Xavier, Odirlei Andre Monticielo
Summary: A systematic review and meta-analysis were conducted to determine muscle strength, muscle mass, and physical function in patients with SLE compared to healthy individuals and patients with RA. The review included 19 studies and the meta-analysis included 11 studies. SLE patients had lower muscle strength than healthy controls and similar muscle mass compared to RA patients and healthy controls. SLE patients with deforming arthropathy had lower muscle strength compared to those without deforming arthropathies.
CLINICAL RHEUMATOLOGY
(2023)
Article
Rheumatology
Yoshiya Tanaka, Tsutomu Takeuchi, Derek Haaland, Stephen Hall, Nevsun Inanc, Zhanguo Li, Ricardo M. M. Xavier, Carlos Cara, Nicola Tilt, Peter C. C. Taylor
Summary: This study assessed the efficacy of Certolizumab pegol (CZP) in patients with early and established rheumatoid arthritis (RA) and found that it was effective in reducing symptoms in patients with different rheumatoid factors (RF) levels. CZP may be considered as a treatment option for RA.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Hermine Brunner, Nikolay Tzaribachev, Ingrid Louw, Inmaculada Calvo Penades, Francisco Avila-Zapata, Gerd Horneff, Ivan J. Foeldvari, Daniel Kingsbury, Maria Eliana Paz Gastanaga, Carine Wouters, Johannes Breedt, Robert Wong, Margarita Askelson, Joe Zhuo, Alberto J. Martini, Daniel Lovell, Nicolino Ruperto
Summary: This study aimed to investigate the frequency and trajectories of individual patients with polyarticular-course juvenile idiopathic arthritis (JIA) achieving various composite end points on abatacept treatment. The results showed that patients achieved composite end points of low disease activity (LDA) with minimal pain, LDA with Childhood Health Assessment Questionnaire disability index score of 0, and 50% improvement in American College of Rheumatology criteria for JIA (ACR50) with minimal pain at 4 months. The proportion of patients meeting these end points increased over 21 months of abatacept treatment.
ARTHRITIS CARE & RESEARCH
(2023)
Article
Rheumatology
Laura E. Schanberg, Lily (Yeruk) Mulugeta, Bolanle Akinlade, Hermine I. Brunner, Jianmeng Chen, Robert A. Colbert, Vincent Delgaizo, Marc R. Gastonguay, Rachel Glaser, Lisa Imundo, Daniel J. Lovell, Jocelyn H. Leu, Nael M. Mostafa, Robert M. Nelson, Peter A. Nigrovic, Nikolay P. Nikolov, Lisa G. Rider, Rebecca Rothwell, Chandrahas Sahajwalla, Renu Singh, Vikram Sinha, Carolyn L. Yancey, Lynne Yao
Summary: This report summarizes a workshop on drug development for polyarticular juvenile idiopathic arthritis (pJIA), highlighting the importance of accelerating drug development and the necessity of collaboration between stakeholders.
ARTHRITIS & RHEUMATOLOGY
(2023)
Article
Rheumatology
Ellen M. Cody, Bridget E. Wilson, Ekemini A. Ogbu, Jennifer L. Huggins, Chen Chen, Tingting Qiu, Tracy Ting, Francisco Flores, Bin Huang, Hermine Brunner
Summary: This study compared three treat-to-target (T2T) states and their association with the prognosis of childhood-onset SLE (cSLE). It found that patients with lupus nephritis and pre-existing damage were at higher risk of disease worsening, and suggested using the lupus low disease activity state (LLDAS) as the preferred T2T measure.
LUPUS SCIENCE & MEDICINE
(2023)
Review
Rheumatology
Peter C. Taylor, Ernest Choy, Xenofon Baraliakos, Zoltan Szekanecz, Ricardo M. Xavier, John D. Isaacs, Sander Strengholt, Julie M. Parmentier, Ralph Lippe, Yoshiya Tanaka
Summary: Janus kinases (JAKs) are a family of cytosolic tyrosine kinases that regulate cytokine signal transduction. Several small-molecule JAK inhibitors (JAKis) are now approved for the treatment of immune-mediated inflammatory diseases. Each JAKi has a unique chemical structure, resulting in a distinctive mode of binding and pharmacological characteristics. Differences also exist in selectivity, off-target effects, and various other factors. This review discusses the pharmacological profiles of specific JAKis.
Review
Rheumatology
Alisson Pugliesi, Amanda Borges de Oliveira, Ana Beatrice Oliveira, Ricardo Xavier, Licia Maria Henrique da Mota, Manoel Barros Bertolo, Miguel Angel Gonzalez-Gay, Gustavo Citera, Luiz Sergio Fernandes de Carvalho
Summary: The efficacy of rituximab, tocilizumab, and abatacept was compared in individuals with refractory rheumatoid arthritis. Abatacept was found to increase the chance of achieving ACR70 response by 2.2-fold compared to tocilizumab.
ADVANCES IN RHEUMATOLOGY
(2023)
Article
Rheumatology
Hermine Brunner, Aisha Vadhariya, Christina Dickson, Wallace Crandall, Casey Kar-Chan Choong, Julie A. Birt, Nicolino Ruperto, Athimalaipet Ramanan
Summary: This study examined treatment regimens and patterns in childhood-onset SLE (cSLE) and adult-onset SLE (aSLE) cohorts, finding similarities in treatment plans, duration, and adherence. Treatment for cSLE involved more intensive medication use, highlighting the need for safe medications approved for cSLE.
LUPUS SCIENCE & MEDICINE
(2023)
Article
Rheumatology
Robert C. Brucia, Kristen Hayward, Hermine I. Brunner, Maricarmen Lopez-Pena, Susan Shenoi, Arzu Soybilgic, James J. Nocton
Summary: A practice analysis process was used to define the scope of clinical practice of pediatric rheumatology. The resulting documents, including a practice analysis document (PAD) and a test content outline (TCO), can be used to improve training and create relevant certification examinations.
ACR OPEN RHEUMATOLOGY
(2023)
Article
Genetics & Heredity
Juliana da Silveira Schauren, Amanda Henrique de Oliveira, Camila Rosat Consiglio, Odirlei Andre Monticielo, Ricardo Machado Xavier, Natalia Schneider Nunes, Joel Henrique Ellwanger, Jose Artur Bogo Chies
Summary: This study investigated the impact of CCR5 promoter region polymorphisms on the development of systemic lupus erythematosus (SLE) and found that CCR5 Delta 32 polymorphism confers protection against the disease in European-derived patients and susceptibility to class IV nephritis in African-derived patients.
INTERNATIONAL JOURNAL OF IMMUNOGENETICS
(2023)